The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 17, 2021
Filed:
Sep. 14, 2016
Applicant:
Baylor College of Medicine, Houston, TX (US);
Inventors:
Andrew Sikora, Houston, TX (US);
Padmini Jayaraman, Houston, TX (US);
Falguni Parikh, Houston, TX (US);
Robin Parihar, Houston, TX (US);
Assignee:
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2015.01); A61K 35/26 (2015.01); A61K 35/28 (2015.01); C12N 5/0789 (2010.01); A61P 35/00 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 35/15 (2013.01); A61K 35/26 (2013.01); A61K 35/28 (2013.01); A61P 35/00 (2018.01); C12N 5/0647 (2013.01); A61K 39/00 (2013.01); A61K 45/06 (2013.01); A61K 2035/124 (2013.01); C12N 2501/15 (2013.01);
Abstract
Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-β1, and in specific embodiments the exposure to TGF-β1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity.